BMS-986158 |
| Catalog No.GC32812 |
Le BMS-986158 est un puissant inhibiteur de BET avec des IC50 de 6,6 et 5nM dans les cellules NCI-H211 du cancer du poumon À petites cellules (SCLC) et les cellules MDA-MB231 du cancer du sein triple négatif (TNBC), respectivement.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1800340-40-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins.
BMS-986158 is an inhibitor of the bromodomain (BRD) and extra-terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor BMS-986158 binds to the acetyl-lysine binding site in the BRD of BET proteins, thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes, resulting in an inhibition of tumor cell growth[2].
[1]. von Schaper E. Roche bets on bromodomains. Nat Biotechnol. 2016 Apr;34(4):361-2. [2]. BET Inhibitor BMS-986158.
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *